-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

Benzinga·12/19/2025 15:07:36
Listen to the news
Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and raises the price target from $17 to $25.